WVU Medicine Princeton Community Hospital pairs up with WVU Medicine Children's to strengthen pediatric care
According to a press release, the family-friendly event will afford the community a chance to meet staff members that care for children in the area and discover more about the affiliation's offerings.
Strawberry Festival prepares return to Alderson in 2025
Guests of the event can partake in giveaways, demonstrations, games, face painting, and more. Entertainment will be provided in the form of a performance from the PikeView Marching band, the release stated. Atlas, the WVU Medicine Children's therapy dog will also be in attendance.
We are excited to invite families in the community to see firsthand the incredible pediatric services now available through our partnership with WVU Medicine Children's. This event is a celebration of our continued commitment to providing compassionate, expert care for children and families throughout southern West Virginia.
Karen Bowling | President and CEO, WVU Medicine Princeton Community Hospital
'Chalk the Walk' gives an artistic spin to a sensitive subject
The partnership allows for access to high-quality children's care closer. Patients will also have access to expanded services with one of the nation's leading hospitals for kids.
Families will also have the comfort of knowing their child's care team is backed by the expertise and resources of WVU Medicine Children's, the release noted. This includes chances to be involved in clinical research, shared safety standards, and coordinated care.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Journals
6 hours ago
- Business Journals
Atlas Men's Health to open first Manhattan clinic
Atlas Men's Health will open its first Manhattan location this fall. The Long Island-based men's health clinic will occupy a 3,800-square-foot space on the sixth floor of 505 Eighth Ave. in Midtown. The location will serve as the clinic's general and executives offices as well as a site for patient consultations and services. The lease is for five years. GET TO KNOW YOUR CITY Find Local Events Near You Connect with a community of local professionals. Explore All Events GFP Real Estate, the landlord, was represented in-house by Allen Gurevich while Atlas Men's Health was represented by Inc.'s Uriel Gandelman on the deal. 'Atlas is opening a location in Midtown Manhattan to make care more accessible for patients who live or work in the city,' Jenny Kaur, regional director at Atlas Men's Health, said in an email statement. 'By expanding into Midtown, Atlas is meeting the growing demand for men's health services while providing greater convenience and visibility in a central location.' Atlas Men's Health currently has one location in Long Island's East Meadow hamlet. The new tenant will join a roster at 505 Eighth Ave. that includes advertising company Mesmerize Media, nonprofit Cicatelli Associates Inc. and law firm Shankar Ninan & Co. LLP. The 25-story, 275,000-square-foot office building, which was originally known as the Hoover Building, features a modernized, 24/7 attended lobby. Sign up for the Business Journal's free daily newsletter to receive the latest business news impacting New York.
Dominion Post
09-08-2025
- Dominion Post
The importance of readiness: AED brings lifesaving access to Miracle Field
MORGANTOWN — A new automated external defibrillator is now on-site at Miracle Field in Mylan Park thanks to a collaboration between SteppingStones, WVU Medicine Children's Heart Center and Project ADAM. This new addition will bring faster response times in the event of cardiac emergencies at the field, which hosts adaptive baseball games for children and adults with disabilities through the Miracle League. 'This is about being prepared for the moment you hope never happens,' said Monica Marietta, executive director of SteppingStones. 'We have always had an AED at our facility, but that is across the parking lot. Now, if something happens to an athlete, a coach, a parent or anyone, this AED is right here.' The device was contributed through Project AED 365 and coordinated locally through Heartbeats of Hope, the West Virginia affiliate of Project ADAM, located at WVU Medicine Children's. Project ADAM was founded after a teenage athlete named Adam Lemel, a 17-year-old high-schooler from Wisconsin, collapsed and died during a basketball game due to sudden cardiac arrest. His parents later learned he might have survived had an AED been available. Since then, Project ADAM (Automated Defibrillators in Adam's Memory) has helped place AEDs in schools and communities across the country. 'The chance of survival goes up dramatically when an AED is used within three minutes,' said Tracy Coup, nurse practitioner and co-coordinator for Project ADAM at WVU Medicine Children's. 'You do not know when or where someone might go down. That is why access and training matter.' While the initiative does not provide AEDs directly, Project ADAM affiliates like WVU Medicine Children's help connect the community to donors and to guide them through the goal of becoming 'Heart Safe.' Becoming heart safe does not mean to just have a device on-site, but have trained staff, emergency plans and annual drills. The new automated external defibrillator acquired through Project ADAM and will be located at the Miracle Field at Mylan park in efforts to improve staying prepared. Cassidy Roark/ The Dominion Post 'It is not just about having an AED on the wall,' said Ashley Watson, also a Project ADAM co-coordinator. 'People have to know what sudden cardiac arrest looks like, where the AED is, how to use it, and how to respond fast. We work with schools and community sites across West Virginia to build that system.' Coup said the team has received 12 'save' reports this school year across the country. This means there are instances where an AED placed through Project ADAM was used and helped save a life during a cardiac emergency. This reflects the importance of readiness, she added. West Virginia law does require that AEDs be present at all school athletic events, and Project ADAM's initiative helps make the process more precise and structured. Going back to Mylan Park, the new AED is part of the border mission of SteppingStones to ensure safety and inclusion. The organization also recently opened an all inclusive playground right next to Miracle Field. 'Whether it is a kid with autism or a grandparent cheering from the stands, we want everyone to feel safe and welcome,' she said. Thanks to this project, we are more prepared than ever.' For more information about Heartbeats of Hope and Project ADAM training or designation, visit and navigate to the Heartsbeats of Hope page.
Yahoo
10-07-2025
- Yahoo
Renasant Bio Launches to Pioneer Next-Generation Disease-Modifying Small Molecule Treatments for ADPKD
Advancing corrector and potentiator programs to address underlying biology of autosomal dominant polycystic kidney disease (ADPKD) across multiple mutations Team includes preeminent scientific leaders in ADPKD; rapid discovery and development efforts powered by suite of proprietary assays $54.5 million in seed financing led by founding investor 5AM Ventures alongside Atlas Venture, OrbiMed and Qiming Venture Partners USA BERKELEY, Calif., July 10, 2025--(BUSINESS WIRE)--Renasant Bio (Renasant), announced its launch today to advance next-generation disease-modifying treatments for autosomal dominant polycystic kidney disease (ADPKD), the leading genetic cause of end-stage renal failure. Renasant is developing a pipeline of oral small molecule corrector and first-in-class potentiator therapies that directly target the underlying biology of ADPKD, with the goal of restoring the function of key polycystin proteins across multiple different mutations to halt disease progression. Renasant has raised $54.5 million in seed funding, co-led by founding investor 5AM Ventures, alongside other leading life sciences investors including Atlas Venture, OrbiMed and Qiming Ventures. The seed financing will support further progression of Renasant's lead corrector program and ongoing discovery efforts for the company's first-in-class potentiator program. "ADPKD is a devastating genetic disorder that affects more than 12 million people globally and still lacks truly disease-modifying therapies," said Emily Conley, Ph.D., chief executive officer of Renasant. "Our platform of differentiated correctors and first-in-class potentiator therapies are designed to directly address the underlying cause of ADPKD across its broad mutation spectrum, offering the potential to benefit the vast majority of patients." Next-Generation Corrector and Potentiator Programs for ADPKD Autosomal Dominant Polycystic Kidney Disease (ADPKD) Autosomal dominant polycystic kidney disease is a chronic, progressive genetic condition marked by the progressive formation of fluid-filled cysts in the kidneys, often leading to end-stage renal failure. The condition arises from mutations in the PKD1 and PKD2 genes, which encode polycystin proteins PC1 and PC2—critical regulators of kidney cell function. The genetic mutations underlying ADPKD are extremely heterogeneous, with no single mutation found in more than 2% of patients. Disease-modifying strategies that correct or potentiate polycystin biology must overcome this diversity—making therapies that work broadly across mutations a key treatment advancement for ADPKD. Current therapies do not directly address the underlying protein dysfunction and are limited in their applicability and tolerability. Addressing the Underlying Biological Drivers of ADPKD Renasant's therapeutic strategy is centered on restoring the normal function of PC1 and PC2. Through its leading expertise in ADPKD biology, including electrophysiology and polycystin channel physiology, Renasant has developed proprietary assays to assess protein trafficking and other key mechanisms, enabling precision-guided development of novel therapies for ADPKD. The company's lead program is a small molecule corrector designed to work across a wide range of disease-causing mutations to stabilize and properly fold PC1/2, promoting protein trafficking to restore kidney function. The program is currently progressing through preclinical development. In addition, Renasant is advancing discovery efforts toward a potentiator to enhance ion flux through the polycystin channel and support anti-cystogenic signaling—a first-in-class approach in ADPKD. Correctors and potentiators can act as stand-alone therapies, or they can be combined for synergistic effect. "Our corrector program is designed to work across a broad range of mutations, and our potentiator represents a novel mechanism of action in ADPKD," said Gus Gustafson, Ph.D., chief scientific officer. "These programs hold the potential to reshape the treatment landscape. We are very encouraged by our preclinical data and committed to rapidly advancing these programs for patients in urgent need." Team of Leading Experts in ADPKD Renasant is led by a world-class team with deep expertise in ADPKD biology and a proven track record in building biopharma companies. The team includes researchers who have shaped the field of polycystin biology and electrophysiology, seasoned drug developers, and biotech executives experienced in advancing cutting-edge scientific approaches. "5AM Ventures founded Renasant around a bold idea: that we could change the trajectory of ADPKD," said Deborah Palestrant, Ph.D., partner at 5AM Ventures. "ADPKD is one of the most complex diseases in renal medicine, but Renasant has assembled the right team, with years of research experience in polycystic disease that has informed the right scientific approach. We're proud to have supported the company from the start and are energized by its progress and commitment to delivering truly disease-modifying treatments for ADPKD patients." Renasant's executive team includes: Emily Conley, Ph.D., chief executive officer Gus Gustafson, Ph.D., chief scientific officer B. Barry Touré, Ph.D., senior vice president, drug discovery Rachel Gallagher, Ph.D., vice president, biology Michelle Ho Huey, Ph.D., vice president, strategy & operations Renasant's board of directors includes: Natalie Holles, chair of the board Kevin Bitterman, Ph.D., partner, Atlas Venture Evan Caplan, M.D., principal, OrbiMed Emily Conley, Ph.D., chief executive officer Anna French, D. Phil, managing partner, Qiming Venture Partners USA Charlotte McKee, M.D., chief medical officer, Sionna Therapeutics Deborah Palestrant, Ph.D., partner, 5AM Ventures In addition, Renasant has assembled a scientific advisory board consisting of preeminent leaders in ADPKD genetics, biology, and both preclinical and clinical drug development. About Renasant Bio Renasant Bio is a biopharmaceutical company pioneering disease-modifying oral small molecule treatments for autosomal dominant polycystic kidney disease (ADPKD), the leading genetic cause of end-stage renal failure. Renasant is advancing a pipeline of oral small molecule corrector and potentiator programs that target the underlying biology of ADPKD to restore the function of key proteins to halt disease progression. Renasant was founded by and incubated within the 4:59 Initiative, the company creation engine of 5AM Ventures, and is based in Berkeley, California. For more information, please visit us at and follow us on LinkedIn and X. View source version on Contacts Media Katie Engleman1ABkatie@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
